CD8A and neoplasm: Sixty-three days after completing immunizations, GUCY2C-specific CD8+ T-cell memory assessed by ELISpot or tumor challenge demonstrated that boosting with Lm-GUCY2C substantially enhanced GUCY2C-specific CD8+ T-cell counts (Supplementary Fig. S2B), reduced metastatic tumor burden (Supplementary Fig. S2C), and improved overall survival (25 vs >90 days; Supplementary Fig. S2D) compared to mice that received only adenovirus-based priming.